Business Wire

BEYOND Developments Reveals a New Vision for Purposeful Living on Dubai Islands with SIORA

11.12.2025 19:02:00 EET | Business Wire | Press release

Share

BEYOND Developments, the bold and design-led real estate developer shaping next-generation waterfront destinations in the UAE, today unveiled SIORA, its first beachfront masterplan on Dubai Islands and the company’s second large-scale community within a year. The launch underscores BEYOND’s accelerated growth and strong alignment with Dubai’s future urban vision.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211014389/en/

BEYOND Developments - SIORA Masterplan at sunset - Dubai Islands (Photo: AETOSWire)

Spanning over 2M square feet, SIORA is conceived as a coastal sanctuary inspired by Japanese garden philosophies, including the pursuit of Ikigai, the Japanese concept of finding purpose and fulfilment in everyday life. In this context, it reflects a philosophy of creating spaces that bring clarity, balance, and a sense of meaning, where architecture nurtures wellbeing and restores harmony between people, nature, and place.

Commenting on the launch, Adil Taqi, CEO of BEYOND Developments, said: “Since its inception in 2024, BEYOND had an exceptional journey with nine launches in 2025 that delivered opportunities for a wider audience to experience a richer and more meaningful life. Today, I am thrilled to announce the launch of SIORA, the company’s second cluster masterplan and bold new expansion into beachfront destinations, spanning over2 million sqft with 2.7 million sqft of GFA on the beautiful Dubai Islands.”

This masterplan aims to define the next generation of urban coastal living, in line with Dubai’s inspirational 2040 Urban Master Plan that puts wellbeing, walkability, and nature at the heart of community life. It embodies our vision for future waterfront living environments where where design excellence, natural beauty, and emotional connection come together to empower people to live balanced experiences and connect purposefully with nature and the community,” added Taqi.

Over the past year, BEYOND has delivered nine launches, welcomed residents and investors from over 40 countries, and exceeded AED 10 billion in sales, a trajectory that reflects the company’s momentum and the market’s trust in its design-led approach.

Taqi emphasised:SIORA represents the next phase of BEYOND’s expansion across Dubai’s coastline. It reflects our commitment to creating thoughtfully designed communities that carry lasting value and deeper meaning for a global audience. SIORA will introduce a new benchmark for waterfront living on Dubai Islands, a complete coastal ecosystem of homes, hospitality, and lifestyle experiences.

SIORA is planned as a pedestrian coastal district where nature shapes the rhythm of daily life. More than 70 percent of the masterplan is dedicated to open green spaces, creating over 1.5M sqft of landscapes that enhance comfort and bring people closer to the coastline. Along 6 km of continuous beachfront, the sea becomes an integral part of community living and outdoor wellbeing.

Shaded routes and landscaped terraces encourage effortless movement and social connection throughout the day. These pathways introduce cooler microclimates and frame calming outlooks toward the water and the horizon, enabling a lifestyle that feels active, grounded, and human. As a defining layer of placemaking, curated cultural and artistic expressions enrich SIORA’s public realm, introducing sculptural installations influenced by Japanese aesthetics to enhance identity and transform every journey into an inspiring cultural experience.

Sustainability is embedded into SIORA’s design through wind, water, and light. Inspired by Japanese garden philosophy, these natural forces shape ventilation, comfort, and climate balance, elevating Dubai Islands living through thoughtful design and a purpose-driven coastal vision. This begins BEYOND’s multi-phase presence on Dubai Islands, elevating design-led waterfront living and shaping the future of Dubai’s coastline.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251211014389/en/

Contacts

Lina Saeed
Junior Account Manager
Tel. + 971585751699
lina@gambit.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye